A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Lenalidomide stabilizes protein-protein complexes by turning labile intermolecular H-bonds into robust interactions
Targeted protein degradation (TPD) is emerging as a very promising strategy to modulate protein activities in several diseases, spearheaded by anti–myeloma drugs lenalidomide and pomalidomide. It has been recently demonstrated that the mechanism of action of these drugs involves the increased degradation of several proteins, including the transcription factors Ikaros and Aiolos as well as the enzyme Caseine Kinase 1 alpha (CK1a). It has been shown that lenalidomide and pomalidomide are able todoi:10.26434/chemrxiv-2022-3kpgm-v2 fatcat:zrewu3e25ja3nfqksqn5wosqba